Bingliang Lin

机构：Sun Yat-sen University, Chinese PLA General Hospital, Third Affiliated Hospital of Sun Yat-sen University · ORCID：0000-0003-4069-6287

发表论文 104 篇 · 总被引 2353 次 · h-index 22

代表论文

• CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis (2024 · Molecular Cancer · 被引 73)
• Interferon‐γ + Th1 activates intrahepatic resident memory T cells to promote HBsAg loss by inducing M1 macrophage polarization (2024 · Journal of Medical Virology · 被引 13)
• Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial (2025 · Nature Medicine · 被引 12)
• Med1 inhibits ferroptosis and alleviates liver injury in acute liver failure via Nrf2 activation (2024 · Cell & Bioscience · 被引 12)
• Rice-derived recombinant human serum albumin as an alternative to human plasma for patients with decompensated liver cirrhosis: a randomised, double-blind, positive-controlled and non-inferiority trial (2025 · Gut · 被引 11)
• Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19 (2024 · NEJM Evidence · 被引 7)